Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 10/20 | 0.96 |
| ▸ | GNAO1 | P09471 | 10/20 | 0.96 |
| ▸ | GNAI1 | P63096 | 10/20 | 0.96 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 5/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19604164 | 1.00 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1S1PR4 | |
| SCHEMBL28793539 | 1.00 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1S1PR4 | |
| SCHEMBL27763474 | 1.00 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1S1PR4 | |
| SCHEMBL30092298 | 1.00 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1S1PR4 | |
| SCHEMBL19604163 | 1.00 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1S1PR4 | |
| SCHEMBL3265058 | 0.98 | GNAI3 (0.92) | GNAI3GNAO1GNAI1EPHX1S1PR4 | |
| SCHEMBL1070277 | 0.92 | GNAI3 (0.81) | GNAI3GNAO1GNAI1EPHX1S1PR4 | |
| SCHEMBL19606425 | 0.89 | GNAI3 (0.77) | GNAI3GNAO1GNAI1EPHX1S1PR4 | |
| SCHEMBL6247785 | 0.87 | GNAI3 (0.73) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL6097037 | 0.86 | GNAI3 (0.73) | GNAI3GNAO1GNAI1EPHX1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20170321268-A1 | MODIFIED NUCLEOTIDE REAGENTS | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2017-11-09 | — | — | US | disclosed |
| EP-0287696-B1 | ISOQUINOLINE DERIVATIVES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1991-01-02 | — | — | EP | disclosed |
| US-4798897-A | (AMINOALKYL)AMINOSULFONYL-SUBSTITUTED CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1989-01-17 | — | — | US | disclosed |
| EP-0287696-A1 | Isoquinoline derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170321268-A1 | MODIFIED NUCLEOTIDE REAGENTS | POLL, POLN, POLM | GNAI3 1455/4885GNAO1 743/4885GNAI1 1092/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | GNAI3 3676/4885GNAO1 3651/4885GNAI1 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.